Compared to the median DFS of 14.4 months observed among stage IIIA patients in the control arm of the ADAURA study [12], this patient achieved a DFS of 27 months, indicating a positive impact of adjuvant pralsetinib for RET-positive NSCLC patients. The gene discussed is RET; the disease is non-small cell lung carcinoma.